Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283399108> ?p ?o ?g. }
- W4283399108 endingPage "1165" @default.
- W4283399108 startingPage "1164" @default.
- W4283399108 abstract "Background: Mantle cell lymphoma (MCL) is a B-cell tumor which often relapses. BCR inhibitors (Ibrutinib, Acalabrutinib) and antiapoptotic BCL2-family members blockers BH3-mimetics (Venetoclax, ABT-199) are effective drugs to fight MCL. However, the disease remains incurable, due to therapy resistance, even to the promising Venetoclax and Ibrutinib combination. Therefore, there is a profound need to explore novel useful therapeutic targets. CK2 is a S/T kinase overexpressed in several solid and blood tumors. We demonstrated that CK2, operating through a “non-oncogene addiction” mechanism promotes tumor cell survival, and counteracts apoptosis, by activating pro-survival signaling cascades, such as NF-κB, STAT3 and AKT. CK2 could regulate also BCL2 family members. The CK2 chemical inhibitor CX-4945 (Silmitasertib, Sil) is already under scrutiny in clinical trials in relapsed multiple myeloma, solid tumors and COVID-19. Aims: In this work, we tested the effect of CK2 chemical inhibition or knock down on Venetoclax (Ven)-induced cytotoxicity in MCL pre-clinical models to effectively reduce MCL cell growth and clonal expansion. Methods: CK2 expression and BCR/BCL2 related signaling components were analyzed in MCL cells and control cells by Western blotting. CK2 and BCL2 inhibition was obtained with Sil and Ven, respectively and with CK2 gene silencing through the generation of anti-CK2 shRNA IPTG-inducible MCL cell clones. Survival, apoptosis, mitochondrial membrane depolarization and proliferation were investigated by FACS analysis of AnnexinV/PI and JC-10 staining. The synergic action of Ven and Sil was analyzed by the Chou-Talalay combination index (CI) method. CK2 knock down in vivo was obtained in xenograft NOD-SCID mouse models Results: CK2 inactivation (with Sil or CK2 silencing) determined a reduction in the activating phosphorylation of S529 p65/RelA and S473 and S129 AKT, important survival cascades for MCL. Sil or CK2 silencing caused BCL2 and related MCL1 protein reduction, causing cell death. Importantly, we confirmed these results also in an in vivo xenograft mouse model of CK2 knockdown in MCL. Sil +Ven combination increased MCL cell apoptosis, as judged by the augmented frequency of Annexin V positive cells and expression of cleaved PARP protein, and JC-10 mitochondrial membrane depolarization, with respect to the single treatments. Captivatingly, Sil or CK2 gene silencing led to a substantial reduction of the Ven-induced increase of MCL-1, potentially counteracting a deleterious Ven-induced drawback. Analysis of cell cycle distribution confirmed an increased frequency of apoptotic cells in the sub G1 phase in CK2-silenced cells and a modulation of the other phases of the cell cycle. Remarkably, the calculated CI less than 1 suggested a strong synergic cell-killing effect between Sil and Ven, on all the cell lines tested, including those less sensitive or resistant to Ven Summary/Conclusion: We demonstrated that the simultaneous inhibition/knock down of CK2 and BCL2 synergistically cooperates in inducing apoptosis and cell cycle arrest of MCL malignant B-lymphocytes and has the potential of reducing MCL clonal growth, also counterbalancing mechanism of resistance that may arise with Ven. Therefore, CK2 is a rational therapeutic target for the treatment of MCL to be tested in combination with Ibrutinib or Ven." @default.
- W4283399108 created "2022-06-25" @default.
- W4283399108 creator A5000543648 @default.
- W4283399108 creator A5009123864 @default.
- W4283399108 creator A5018601955 @default.
- W4283399108 creator A5042867938 @default.
- W4283399108 creator A5057186037 @default.
- W4283399108 creator A5058373325 @default.
- W4283399108 creator A5061077320 @default.
- W4283399108 creator A5065338875 @default.
- W4283399108 creator A5066814162 @default.
- W4283399108 creator A5069858736 @default.
- W4283399108 creator A5078958639 @default.
- W4283399108 creator A5083450401 @default.
- W4283399108 creator A5090660779 @default.
- W4283399108 date "2022-06-01" @default.
- W4283399108 modified "2023-09-27" @default.
- W4283399108 title "P1279: INHIBITION OF PROTEIN KINASE CK2 AND BCL-2: A NOVEL THERAPEUTIC STRATEGY TO ANTAGONIZE MANTLE CELL LYMPHOMA CELL GROWTH" @default.
- W4283399108 doi "https://doi.org/10.1097/01.hs9.0000847980.27029.cb" @default.
- W4283399108 hasPublicationYear "2022" @default.
- W4283399108 type Work @default.
- W4283399108 citedByCount "0" @default.
- W4283399108 crossrefType "journal-article" @default.
- W4283399108 hasAuthorship W4283399108A5000543648 @default.
- W4283399108 hasAuthorship W4283399108A5009123864 @default.
- W4283399108 hasAuthorship W4283399108A5018601955 @default.
- W4283399108 hasAuthorship W4283399108A5042867938 @default.
- W4283399108 hasAuthorship W4283399108A5057186037 @default.
- W4283399108 hasAuthorship W4283399108A5058373325 @default.
- W4283399108 hasAuthorship W4283399108A5061077320 @default.
- W4283399108 hasAuthorship W4283399108A5065338875 @default.
- W4283399108 hasAuthorship W4283399108A5066814162 @default.
- W4283399108 hasAuthorship W4283399108A5069858736 @default.
- W4283399108 hasAuthorship W4283399108A5078958639 @default.
- W4283399108 hasAuthorship W4283399108A5083450401 @default.
- W4283399108 hasAuthorship W4283399108A5090660779 @default.
- W4283399108 hasBestOaLocation W42833991081 @default.
- W4283399108 hasConcept C185592680 @default.
- W4283399108 hasConcept C190283241 @default.
- W4283399108 hasConcept C203014093 @default.
- W4283399108 hasConcept C2776364478 @default.
- W4283399108 hasConcept C2777478702 @default.
- W4283399108 hasConcept C2777525834 @default.
- W4283399108 hasConcept C2777938653 @default.
- W4283399108 hasConcept C2778461978 @default.
- W4283399108 hasConcept C2779338263 @default.
- W4283399108 hasConcept C2779675984 @default.
- W4283399108 hasConcept C2779878957 @default.
- W4283399108 hasConcept C42362537 @default.
- W4283399108 hasConcept C502942594 @default.
- W4283399108 hasConcept C55493867 @default.
- W4283399108 hasConcept C62112901 @default.
- W4283399108 hasConcept C62478195 @default.
- W4283399108 hasConcept C75217442 @default.
- W4283399108 hasConcept C86554907 @default.
- W4283399108 hasConcept C86803240 @default.
- W4283399108 hasConcept C90059517 @default.
- W4283399108 hasConcept C95444343 @default.
- W4283399108 hasConcept C98274493 @default.
- W4283399108 hasConceptScore W4283399108C185592680 @default.
- W4283399108 hasConceptScore W4283399108C190283241 @default.
- W4283399108 hasConceptScore W4283399108C203014093 @default.
- W4283399108 hasConceptScore W4283399108C2776364478 @default.
- W4283399108 hasConceptScore W4283399108C2777478702 @default.
- W4283399108 hasConceptScore W4283399108C2777525834 @default.
- W4283399108 hasConceptScore W4283399108C2777938653 @default.
- W4283399108 hasConceptScore W4283399108C2778461978 @default.
- W4283399108 hasConceptScore W4283399108C2779338263 @default.
- W4283399108 hasConceptScore W4283399108C2779675984 @default.
- W4283399108 hasConceptScore W4283399108C2779878957 @default.
- W4283399108 hasConceptScore W4283399108C42362537 @default.
- W4283399108 hasConceptScore W4283399108C502942594 @default.
- W4283399108 hasConceptScore W4283399108C55493867 @default.
- W4283399108 hasConceptScore W4283399108C62112901 @default.
- W4283399108 hasConceptScore W4283399108C62478195 @default.
- W4283399108 hasConceptScore W4283399108C75217442 @default.
- W4283399108 hasConceptScore W4283399108C86554907 @default.
- W4283399108 hasConceptScore W4283399108C86803240 @default.
- W4283399108 hasConceptScore W4283399108C90059517 @default.
- W4283399108 hasConceptScore W4283399108C95444343 @default.
- W4283399108 hasConceptScore W4283399108C98274493 @default.
- W4283399108 hasLocation W42833991081 @default.
- W4283399108 hasLocation W42833991082 @default.
- W4283399108 hasLocation W42833991083 @default.
- W4283399108 hasLocation W42833991084 @default.
- W4283399108 hasOpenAccess W4283399108 @default.
- W4283399108 hasPrimaryLocation W42833991081 @default.
- W4283399108 hasRelatedWork W2028681024 @default.
- W4283399108 hasRelatedWork W2242047223 @default.
- W4283399108 hasRelatedWork W2795301499 @default.
- W4283399108 hasRelatedWork W2940436145 @default.
- W4283399108 hasRelatedWork W3096277382 @default.
- W4283399108 hasRelatedWork W3174852839 @default.
- W4283399108 hasRelatedWork W3211371233 @default.
- W4283399108 hasRelatedWork W4206737714 @default.
- W4283399108 hasRelatedWork W4225515604 @default.
- W4283399108 hasRelatedWork W4291016358 @default.
- W4283399108 hasVolume "6" @default.